Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: A pilot study

Journal of Endocrinological Investigation

Volumn 37, Issue 4, 2014, Pages 401-411

  Francomano, D ^a   Bruzziches, R ^a   Barbaro, G ^a   Lenzi, A ^a   Aversa, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Carotid artery intima media thickness; Endothelial function; Epicardial adipose tissue; Left ventricular mass and function; Male hypogonadism; Testosterone replacement therapy

Indexed keywords

DIPIVEFRINE; FIBRINOGEN; LIPID; TESTOSTERONE UNDECANOATE; HUMAN GROWTH HORMONE; TESTOSTERONE;

ADULT; ANDROGEN THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FIBRINOGEN BLOOD LEVEL; HEART EJECTION FRACTION; HEART PERFORMANCE; HUMAN; HYPOGONADISM; LOW CALORY DIET; MALE; MICROALBUMINURIA; OBESITY; OBSERVATIONAL STUDY; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; PILOT STUDY; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR SYSTEM; COMPLICATION; DRUG EFFECTS; EXERCISE; GLUCOSE TOLERANCE TEST; HORMONE SUBSTITUTION; MIDDLE AGED; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

BLOOD PRESSURE; BODY COMPOSITION; CARDIOVASCULAR SYSTEM; CAROTID INTIMA-MEDIA THICKNESS; DIET, REDUCING; ENDOTHELIUM, VASCULAR; EXERCISE; FIBRINOGEN; GLUCOSE TOLERANCE TEST; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOGONADISM; LIPIDS; MALE; MIDDLE AGED; OBESITY; PILOT PROJECTS; TESTOSTERONE;

EID: 84900556890     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-014-0066-9     Document Type: Article

References (47)

1. Ogden CL, Carroll MD, Curtin LR et al (2006) Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295:1549-1555
2. Janssen I, Mark AE (2007) Elevated body mass index and mortality risk in the elderly. Obes Rev 8:41-59
3. Francomano D, Bruzziches R, Natali M, Aversa A, Spera G (2010) Cardiovascular effect of testosterone replacement therapy in aging male. Acta Biomed 81:101-106
4. Saad F, Gooren LJ (2011) The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes. doi:10.1155/2011/471584
5. Tsai EC, Boyko EJ, Leonetti DL et al (2000) Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord 24:485-491
6. Katznelson L, Finkelstein JS, Schoenfeld DA et al (1996) Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81:4358-4365
7. Kapoor D, Malkin CJ, Channer KS et al (2005) Androgens, insulin resistance and vascular disease in men. Clin Endocrinol 63:239-250
8. Srikanthan P, Karlamangla AS (2011) Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third national health and nutrition examination survey. J Clin Endocrinol Metab 96:2898-2903
9. Traish AM, Saad F, Guay A (2009) The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 30:23-32
10. Wehr E, Pilz S, Boehm BO et al (2011) Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur J Heart Fail 13:482-488
11. Malkin CJ, Pugh PJ, Morris PD et al (2010) Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96:1821-1825
12. Mammi C, Calanchini M, Antelmi A et al (2012) Androgens and adipose tissue in males: a complex and reciprocal interplay. Int J Endocrinol 2012:789653. doi:10.1155/2012/789653
13. Migliaccio S, Francomano D, Bruzziches R. et al (2013) Trunk fat negatively influences skeletal and testicular functions in obese men: clinical implications for the aging male. Int J Endocrinol, Article ID 182753, p 6. doi:10.1155/2013/182753
14. American Diabetes Association (2011) Standards of medical care in diabetes - 2011. Diabetes Care 34:S11-S61
15. Lunenfeld B, Mskhalaya G, Kalinchenko S, Tishova Y (2013) Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. Aging Male 16:143-150
16. Iacobellis G, Willens HJ, Barbaro G, Sharma AM (2008) Threshold values of high-risk echocardiographic epicardial fat thickness. Obesity (Silver Spring) 16:887-892
17. Aversa A, Bruzziches R, Francomano D et al (2010) Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 7:3495-3503
18. Aversa A, Francomano D, Bruzziches R et al (2011) The application of digital pulse amplitude tonometry to the diagnostic investigation of endothelial dysfunction in men with erectile dysfunction. Andrologia 43:9-15
19. Palmieri L, Panico S, Vanuzzo D et al (2004) Gruppo di Ricerca del Progetto CUORE. Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score. Ann Ist Super Sanità 40:393-399
20. Aversa A, Bruzziches R, Francomano D et al (2012) Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male 15:96-102
21. Vitale C, Marazzi G, Iellamo F et al (2012) Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. Int J Cardiol 155:279-284
22. Iacobellis G, Willens HJ (2009) Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 22:1311-1319
23. Iacobellis G, Corradi D, Sharma AM (2005) Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2:536-543
24. Seidell JC, Bjorntorp P, Sjostrom L et al (1990) Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 39:897-901
25. Svartberg J (2007) Epidemiology: testosterone and the metabolic syndrome. Int J Impot Res 19:124-128
26. Khan MF, Movahed MR (2013) Obesity cardiomyopathy and systolic function: obesity is not independently associated with dilated cardiomyopathy. Heart Fail Rev 18:207-217. doi:10.1007/s10741-012-9320-4
27. Wong CY, O'Moore-Sullivan T, Leano R et al (2004) Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 110:3081-3087
28. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS (2002) Obesity and the risk of heart failure. N Engl J Med 347:305-313
29. Rosito GA, Massaro JM, Hoffmann U et al (2008) Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 117:605-613
30. Mookadam F, Goel R, Alharthi MS, Jiamsripong P, Cha S (2011) Epicardial fat and its association with cardiovascular risk: a cross-sectional observational study. Heart Views 11:103-108
31. Tamarappoo B, Dey D, Shmilovich H et al (2010) Increased pericardial fat volume measured from noncontrast CT predicts myocardial ischemia by SPECT. JACC Cardiovasc Imaging 3:1104-1112
32. Cheng VY, Dey D, Tamarappoo B et al (2010) Pericardial fat burden on ECG-gated noncontrast CT in asymptomatic patients who subsequently experience adverse cardiovascular events. JACC Cardiovasc Imaging 3:352-360
33. Cavalcante JL, Tamarappoo BK, Hachamovitch R et al (2012) Association of epicardial fat, hypertension, subclinical coronary artery disease, and metabolic syndrome with left ventricular diastolic dysfunction. Am J Cardiol 110:1793-1798
34. Andersen NH, Bojesen A, Kristensen K et al (2008) Left ventricular dysfunction in Klinefelter syndrome is associated to insulin resistance, abdominal adiposity and hypogonadism. Clin Endocrinol 69:785-791
35. Pasquali D, Arcopinto M, Renzullo A et al (2013) Cardiovascular abnormalities in Klinefelter syndrome. Int J Cardiol 168:754-759
36. Aversa A, Bruzziches R, Francomano D, Spera G (2010) Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest 33:776-783
37. Bhasin S, Storer TW, Berman N et al (1996) The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335:1-7
38. Heufelder AE, Saad F, Bunck MC, Gooren L (2009) Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 30:726-733
39. Schwarz ER, Willix RD Jr (2011) Impact of a physician-supervised exercise-nutrition program with testosterone substitution in partial androgen-deficient middle-aged obese men. J Geriatr Cardiol 8:201-206
40. Iellamo F, Rosano GM, Volterrani M (2010) Testosterone deficiency and exercise intolerance in heart failure: treatment implications. Curr Heart Fail Rep 7:59-65
41. Volterrani M, Rosano GM, Iellamo F (2012) Testosterone and heart failure. Endocrine 42:272-277
42. Caminiti G, Volterrani M, Iellamo F et al (2009) Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a doubleblind, placebo-controlled, randomized study. J Am Coll Cardiol 2054:919-927
43. Vigen R, O'Donnell CI, Barón AE et al (2013) Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310:1829-1836
44. Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH, Channer K (2009) Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol 161:443-449
45. Tirabassi G, Gioia A, Giovannini L et al (2013) Testosterone and cardiovascular risk. Intern Emerg Med 8(Suppl 1):S65-S69
46. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM (2012) Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 97:2050-2058
47. Toma M, McAlister FA, Coglianese EE et al (2012) Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 5:315-321